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expensive as compared to colonoscopy or barium enema,
which may cost more than $1000.00. A guaiac-based test
was utilized costing approximately $0.81 per test.
METHOD: Patients in primary care were included in
routine preventive screening to include FOBTs. We eval-
uated 2021 FOBTs during FY1997.
RESULTS: $1637.01 was spent screening 2021 patients.
Four asymptomatic patients were detected to have colon
cancer as a result of this screening. One potential death
was prevented for every 505.25 patients screened.
CONCLUSION: In certain managed care patient popula-
tions, this may be an even more cost-effective approach
in colorectal screening.
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OBJECTIVE: In a cost analysis we compared the socio-
economic relevance of diagnostic screening to differenti-
ate type 2 diabetes mellitus patients with autoantibodies
from type 2 patients without screening. As the prevalence
of antibodies is—compared to older or younger pa-
tients—enhanced at the age of 30 to 45, this analysis fo-
cussed on this population of diabetes mellitus type 2 aged
30 to 45 years.
METHODS: In a decision tree analysis two groups of pa-
tients with diabetes mellitus one with and one without
screening were compared. Endpoints were diabetes associ-
ated late complications as myocardial infarction, stroke,
proliferative nephropathy, proliferative retinopathy, ma-
jor amputation caused by diabetic foot lesion. Costs of di-
abetes treatment are calculated over a period of 20 years
considering the high prevalence of late complications after
20 years duration of the disease. Costs of diabetes-associ-
ated late complications are analyzed over a period of 1
year. This analysis included both direct and indirect costs.
The model examined the costs from the perspective of the
payer (German sickness fund).
RESULTS: Over a period of 20 years total costs for diag-
nostic screening per patient amounts to DM 31,278 in-
cluding DM 7799 for direct and DM 23,479 for indirect
costs. The control group revealed total costs per patient of
DM 35,290 while direct costs amount to DM 10,984 and
indirect costs to DM 24,306. The projection of the total
population results in a cost saving potential of DM 2.6 bil-
lion after investment of DM 22.8 million for screening.
The model’s robustness was proved in sensitivity analyses.
CONCLUSION: Autoantibody screening of 30- to 45-
year-old diabetes mellitus patients reduces healthcare ex-
penditures as it decreases the prevalence of diabetes asso-
ciated late complications.
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Literature indicates that mammography screening is cost-
effective for detecting early-stage breast cancer in high-
risk populations compared to other medical interven-
tions. Mammographic interpretations are typically lim-
ited to single readers and studies do not necessarily ac-
count for the costs and effects associated with double
reading (mammography interpretation by two radiolo-
gists), when practiced. Compared to single reading (SR),
double reading (DR) has been shown to increase sensitiv-
ity although its effects on specificity and on costs and
outcomes are not clear.
OBJECTIVE: To review current literature regarding SR
and DR to assess 1) the value of DR and 2) the need for
cost-effectiveness analyses of DR versus SR.
METHODS: A review of clinical and economic literature
of SR and DR was performed.
RESULTS: A limited number of studies indicate that the
cost-effectiveness of DR depends upon the approach used.
Specifically, a difference emerges between consensus DR
(where two radiologists achieve agreement on interpreta-
tion) and independent DR. Overall, findings show that con-
sensus DR may be cost-effective compared to SR by increas-
ing sensitivity (by 5% to 15%) while decreasing the recall
rate (or increasing specificity) by 2% to 10%. In contrast,
independent DR appears to increase the recall rate at added
costs and therefore, may not be cost-effective.
CONCLUSION: An increase in sensitivity should be
weighed against the decrease in specificity associated with
DR. Additional cost-effectiveness analyses of DR (both in-
dependent and consensus) compared to SR should be con-
ducted to determine the overall value of DR and to guide
health policy decision-making. Cost-effectiveness analy-
ses could also be conducted to evaluate the value of new
computer-aided detection systems designed to improve
sensitivity without compromising specificity.
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OBJECTIVE: Mammography has been well established
as a cost-effective tool in breast cancer screening. How-
ever, low compliance has been a major obstacle to its suc-
cess. The current study is to compare the characteristics
of all programs that aimed at improving mammography
compliance and to examine their effectiveness on an ag-
gregate basis.
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METHOD: A literature review was conducted from
1966 to 1998 to search for all published studies that
aimed at increasing mammography compliance. Each in-
dividual study was examined in terms of its study design,
intervention given, study setting, sample size, compli-
ance, and effectiveness. Statistical analysis to compare ef-
fectiveness was conducted using Chi-Square test.
RESULTS: There were 16 studies identified. They were
all US studies from 1987 to 1994. Study duration was
from 3 to 36 months (median 12.0). The study locations
were inner city (19%), urban (69%), and rural (12%).
Sample size ranged from 63 to 4559 (medium 238). In-
terventions used can be grouped into four categories: mo-
bile van service (2), work-site mammography (4), re-
minder (8), and incentive (2), and their mean increase in
compliance rates was 33.0%, 23.8%, 23.0%, and 4.0%,
respectively. Statistical analysis for effective assessment in
descending order was as follow: mobile van service (RR 
3.74; 95% CI 2.50–5.59), reminder (RR  1.65; 95% CI
1.56–1.75), work-site mammography (RR  1.36; 95%
CI 1.23–1.51), and incentive programs (RR  1.14; 95%
CI 0.77–1.71).
CONCLUSIONS: Our preliminary analysis showed mo-
bile van service as the most effective intervention. How-
ever, since all type of programs could increase compli-
ance, their utility should be assessed based on the relative
costs and other constraints of the delivery system.
TPS5
COST-EFFECTIVENESS ANALYSIS OF GENETIC 
TESTING FOR BREAST CANCER
Luo M, Hay J
Department of Pharmaceutical Economics and Policy, 
University of Southern California, Los Angeles, CA, USA
With the isolation of the breast cancer susceptibility genes,
it is becoming possible to identify individuals who are at
substantially increased risk of developing breast cancer.
OBJECTIVES: The purpose of this study is to evaluate
the cost-effectiveness of genetic testing for breast cancer.
METHODS: A cost-effectiveness model was developed
to determine the impact of genetic testing for breast can-
cer. Data were obtained from medical literature. The tar-
get population of this analysis consisted of women age 30
to 34 who are the first-degree relatives of breast cancer
patients with strong family history. The cost analysis was
performed from the societal perspective, including direct
and indirect costs. All costs were converted to 1998 US
dollars. The results were presented as incremental cost
per life-year saved through genetic testing. All costs and
life-years were discounted to a present value using a 3%
annual discount rate. One-way sensitivity analysis was
used to assess the stability of the results when different
probabilities and assumptions were applied.
RESULTS: A genetic testing program started with 100
breast cancer patients with strong family history resulted
in saving 7.32 discounted life-years of their 150 at-risk
first-degree relatives compared to no testing. With the net
incremental cost at $289,236, the cost-effectiveness ratio
was $39,526 per life-year saved. Even when the parame-
ters were varied in the sensitivity analysis, the results
were robust.
CONCLUSIONS: On the basis of a range of assumptions
this model suggests that genetic testing of women who
have a strong family history of breast cancer may be cost-
effective. Studies that include the impact of genetic test-
ing on quality of life should be pursued in the future.
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OBJECTIVE: To determine the cost-effectiveness of screen-
ing versus no screening for retinopathy in Type I diabetics,
and secondly to determine the cost-effectiveness of screen-
ing every 6 months versus screening every 12 months.
METHODS: Data was compiled from previously pub-
lished articles. The diabetic population was divided into
two groups, one that received screening for diabetic retin-
opathy and one that did not. The group that received
screening were screened either every 6 months or 12
months and the development of diabetic retinopathy was
observed. The endpoint was the progression of the disease
to blindness. This study used the payer’s perspective and
hence only the direct costs of the screening procedure and
treatment of diabetic retinopathy were included in the cost
measures. The outcome measure was the number of sight
years saved as a result of timely screening and treatment.
RESULTS: For the cohort that did not receive screening
post diagnosis, the average total cost was $22,023/person
over 18 years. Total cost of screening and treating the pa-
tient was $8790 per person over 18 years. The total
6-month screening and treatment cost for the cohort that
received screening was $27,651 over 18 years and the
12-month screening cost was $53,257/person. The total
sight years saved for the 6-month and the 12-month screen-
ing was 5 years and 3 years, respectively.
CONCLUSION: Our results illustrate that screening the
patient for diabetic retinopathy is less costly than not
screening the patient. Also, the 6-month screening proce-
dure is significantly more cost-effective than the 12-month
procedure.
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